证券代码：603222 证券简称：济民健康 公告编号：2025-062 济民健康管理股份有限公司 关于完成工商变更登记并换发营业执照的公告 住所：浙江省台州市黄岩区北院路 888 号 统一社会信用代码：91330000610008739T 经营范围：一般项目:健康咨询服务(不含诊疗服务)；技术服务、技术开发、 名称：济民健康管理股份有限公司 注册资本：伍亿贰仟伍佰零玖万零陆佰壹拾伍元 类型：其他股份有限公司（上市） 成立日期：1996 年 12 月 24 日 法定代表人：田云飞 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 济民健康管理股份有限公司（以下简称"公司"）分别于 2025 年 11 月 13 日和 2025 年 12 月 1 日召开的第五届董事会第二十三次会议和 2025 年第一次临 时股东会，审议通过了《关于取消监事会并修订<公司章程>的议案》；于 2025 年 12 月 2 日召开第六届董事会第一次会议，审议通过《关于聘任公司总裁的议 案》，同意聘任田云飞先生为公司总裁，任职自董事会审议通过之日至第六届董 事 ...

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - The company plans to establish a joint venture with Hubei Military-Civilian Technology Innovation Co., Ltd., aiming to enhance its core competitiveness and sustainable development through strategic asset integration and industry transformation [1] Investment Details - The registered capital of the joint venture, Hubei Jimin Military-Civilian Technology Innovation Co., Ltd., is set at 600 million yuan, with the company contributing 294 million yuan for a 49% stake, while the military-civilian technology firm will invest 306 million yuan for a 51% stake [1] Business Context - The company's main business includes medical services, medical devices, and large-volume infusion products, which have faced pressure due to intensified industry competition and external factors such as U.S. tariff policies, leading to a decline in overall performance [1] Strategic Purpose - The establishment of the joint venture is part of the company's long-term strategic planning, focusing on nurturing and integrating quality asset targets to promote industry transformation and upgrade [1]

证券代码：603222 证券简称：济民健康 公告编号：2025-061 济民健康管理股份有限公司 关于发起设立合资公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●济民健康管理股份有限公司（以下简称"公司"）拟与湖北省军民科技创 新有限公司（以下简称"军民科技"）共同设立合资公司湖北济民军民科技创新 有限公司（暂定名，最终以市场监督管理部门核准的名称为准）。 ●投资金额和比例：合资公司注册资本为 60,000 万元，其中，公司认缴出 资 29,400 万元，持股比例为 49%，军民科技认缴出资 30,600 万元，持股比例为 51%，各方均以现金出资。 ●本次交易不构成关联交易，不构成重大资产重组。 ●本次交易已经公司第六届董事会第二次会议审议通过，无需提交公司股东 会审议。 一、对外投资概述 为培育和整合优质标的资产，推动公司产业转型升级，公司拟与军民科技共 同出资 60,000 万元设立湖北济民军民科技创新有限公司（暂定名）。其中，公 司认缴出资 29,400 万元，持股比例为 49%，军民科技 ...

济民健康公告称，拟与军民科技共同出资6亿元设立湖北济民军民科技创新有限公司（暂定名）。其 中，公司认缴2.94亿元，持股49%；军民科技认缴3.06亿元，持股51%，各方均以现金出资。本次交易 已获公司第六届董事会第二次会议通过，不构成关联交易和重大资产重组。公司称，此举旨在培育和整 合资产，推动产业升级，但合资公司运作可能受多种因素影响，存在项目不能按预期实施的风险。 ...

Core Viewpoint - The recent marriage proposal by Liu Xin, a prominent figure in the investment community, has garnered significant online attention, leading to increased interest in his financial background and holdings in multiple listed companies [1][3]. Group 1: Liu Xin's Financial Background - Liu Xin is identified as a major shareholder in over 10 listed companies, with his name appearing in the top ten shareholders of six A-share companies, holding a total of approximately 11.92 billion CNY in stock value [4][5]. - The companies where Liu Xin is a top shareholder include Dajin Heavy Industry, Zhongdian Electric, Dayuan Pump Industry, Jimin Health, Jiangshun Technology, and Longxing Technology, with notable holdings in Dajin Heavy Industry and Jiangshun Technology [4][5]. Group 2: Stock Performance and Market Reactions - Liu Xin's mention of Guosheng Technology in his proposal has led to a significant stock price increase, with the stock rising by 38.41% from the time of his announcement to December 8 [8]. - Guosheng Technology's stock has experienced a dramatic rise, including multiple trading halts, raising questions about the timing of Liu Xin's public disclosure and potential market manipulation [8][10]. Group 3: Acquisition and Regulatory Scrutiny - Guosheng Technology announced a plan to acquire 100% of Fuyue Technology for 240.6 million CNY, which has raised concerns due to the high premium associated with the acquisition [9][10]. - Fuyue Technology, a newly established company, reported minimal revenue and a net loss, leading to regulatory inquiries regarding the fairness and implications of the acquisition [9][10].

（文章来源：每日经济新闻） 济民健康（603222.SH）12月4日在投资者互动平台表示，公司旗下博鳌国际医院是海南博鳌乐城国际 医疗旅游先行区的医院之一，海南封关后，一是"零关税"商品税目比例将大幅提升，医院的药械采购成 本预计会得到进一步降低；另一方面，境外医师执业流程将进一步简化，有利于医院的对外交流合作及 人才引进。 每经AI快讯，有投资者在投资者互动平台提问：贵公司海南博鳌医院海南封管会有积极影响吗？是海 南唯一民营医院吗？ ...

此外，据田云飞介绍，公司此前引发投资者关注的"何清红等人伪造公司印章"案，截至目前，公安机关 已初步查明"何清红等人伪造公司印章"案的基本事实，何清红已由黄岩区检察院批准逮捕，相关案件仍 在进一步侦查中。 （上证路演） (编辑：杨燕 林辰)关键字： 医疗 近日，济民健康举办第三季度业绩说明会，在回答投资者普遍关注的创新药DB006溶瘤腺病毒注射液相 关进展时，济民健康董事兼总裁田云飞表示，DB006溶瘤腺病毒注射液临床试验受理已满60日，博鳌国 际医院未收到国家药监局药品审评中心对DB006临床试验的否定和质疑意见，博鳌国际医院将按计划推 进相关工作。博鳌国际医院DB006项目目前正稳步推进中，尚未正式启动临床试验工作。 博鳌国际医院DB006溶瘤腺病毒注射液是一款用于治疗晚期恶性实体肿瘤的基因治疗药物，该产品利用 基因工程的方法，对溶瘤病毒进行了多个方面的改造，以实现选择性感染肿瘤细胞、增强病毒的肿瘤特 异性复制能力；同时，该产品通过多个抗肿瘤及免疫调节基因的导入，利用多个靶点杀伤肿瘤。截至目 前，全球市场共有5个溶瘤病毒药物获得审批上市，国内市场进入临床试验阶段的溶瘤病毒药物约7个， 多数处于I/II期。 ...

面对网友质疑其征婚是吸引散户接盘的套路，刘鑫称反向交易违法违规，可以通过持仓时长佐证自己的中长期投资理念。 来源：市场资讯 （来源：明见局） 作者｜张典 金融圈年末大瓜太硬核！90后游资大佬刘鑫（网名鑫多多）在个人公众号"亿万鑫"发布征婚启事，直接把财富实力和择偶标准摊在了明面上！ 刘鑫目前是超10家上市公司十大股东、财报披露持仓超12亿元，烟台杭州有房有车，幻影、库里南等豪车在手，要求另一半是"恋爱脑"因为自己也是...... 这波操作让他微信每天被几百人挤爆，而其背后实打实的投资战绩和独特操盘逻辑更让全网疯狂深扒。 根据红星资本局此前报道，作为新生代游资的标杆人物，截至2024年三季度末刘鑫已跻身6家公司前十大流通股东，合计市值达11.5亿元，核心标的包括 大金重工、中电电机、大元泵业、江顺科技、济民健康以及龙星科技。 其中大金重工是他的重仓王牌，持股1226.51万股、占比1.92%，位列第三大股东、第一大自然人股东，对应市值超6亿元，且持有周期超3个月；江顺科技 则以2000多万元持仓坐稳第一大流通股东宝座，龙星科技更是持有超3年，斩获了19.06%回报率。 四季度他的操作更显凌厉，精准抄底国晟科技这 ...

一、董事会会议召开情况： 济民健康管理股份有限公司（以下简称"公司"）第六届董事会第一次会议 于 2025 年 12 月 2 日上午以现场结合通讯表决方式召开，会议通知于 2025 年 11 月 27 日通过电话，邮件及书面形式发出，本次会议由董事徐赞先生主持，应出 席董事 9 名，实际出席董事 9 名。会议的召集，召开符合《公司法》和《公司章 程》的有关规定，会议合法有效。 二、董事会会议审议情况： 证券代码：603222 证券简称：济民健康 公告编号：2025-060 济民健康管理股份有限公司 第六届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 经过与会董事认真审议，形成如下决议： （一）以 9 票同意，0 票反对，0 票弃权审议并通过了《关于选举公司第六 届董事会董事长的议案》。 同意选举徐赞先生为公司第六届董事会董事长，任期至第六届董事会届满之 日为止。 （二）以 9 票同意，0 票反对，0 票弃权审议并通过了《关于选举第六届董 事会专门委员会成员及召集人的议案》。 同意选举以下人员组 ...